Pneumococcal vaccine conjugate 13-valent - Pfizer

Drug Profile

Pneumococcal vaccine conjugate 13-valent - Pfizer

Alternative Names: 13-Valent pneumococcal conjugate vaccine - Pfizer; 13vPnC; PCV 13; PNCRM13; Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) - Pfizer; Prevenar 13; Prevnar 13

Latest Information Update: 30 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer Cochin Hospital; Pfizer; University Hospital of Montpellier
  • Class Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pneumococcal infections

Most Recent Events

  • 23 Feb 2017 Pfizer has patent protection for 13-valent pneumococcal conjugate vaccine in European Union, Japan and USA (Pfizer Form 10-K, February 2017)
  • 02 Nov 2016 Preregistration for Pneumococcal infections (In infants, In children, Prevention) in China (IM) before November 2016
  • 02 Nov 2016 Registered for Pneumococcal infections (In infants, In children, Prevention) in China (IM) in November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top